CAMBRIDGE, Mass. - Omega Therapeutics, Inc. (NASDAQ:OMGA), a biotech company focused on programmable epigenomic mRNA medicines, announced today the appointment of Dr. Kaan Certel as its Chief Business Officer. Dr. Certel is tasked with leading global business development efforts, including the establishment of strategic partnerships.
Dr. Certel joins Omega with over two decades of experience in business development and corporate strategy within the biopharmaceutical industry. His previous roles include Chief Business Officer at BioCity Biopharma and Global Head of Oncology External Innovation at Sanofi (NASDAQ:SNY). His tenure at these companies was marked by significant contributions to portfolio strategy and the establishment of key collaborations.
Mahesh Karande, President and CEO of Omega Therapeutics, expressed confidence in Dr. Certel's ability to drive the company's business development, citing his "successful track record" and "deep scientific grounding." Dr. Certel's own statement reflected his enthusiasm for joining Omega, highlighting the "versatile approach to precision epigenomic control" offered by the company's OMEGA platform.
Omega Therapeutics operates in the field of genomic medicine, aiming to modulate gene expression pre-transcriptionally. The company's OMEGA platform seeks to control gene expression without altering the native nucleic acid sequences, targeting a broad spectrum of diseases, including those considered undruggable.
The information in this article is based on a press release statement from Omega Therapeutics. The company, founded in 2017, has positioned itself at the forefront of epigenomic research, with a pipeline of therapeutic candidates spanning oncology, regenerative medicine, and diseases with multigenic origins.
Dr. Certel's academic background includes a Ph.D. in Genetics from the University of Iowa and a postdoctoral fellowship at MIT's Koch Institute for Integrative Cancer Research. His appointment is part of Omega's broader strategy to expand its business development and pursue new partnerships to advance its therapeutic pipeline.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.